APCs – How much should they cost?





APCs, Article Processing Charges, Open Access, transparency


Watch the VIDEO.

Gold Open Access can be facilitated by an Article Processing Charge (APC), which refers to the author-facing charge levied for publishing an article openly in a specific journal. These charges vary significantly across journals and recently there has been a demand for publishers to be more transparent about how their APCs are calculated. Plan S has clearly set the need for transparency in its principles and implementations stating “When Open Access publication fees are applied, they must be commensurate with the publication services delivered and the structure of such fees must be transparent to inform the market and funders potential standardisation and capping of payments of fees”. This presentation will provide a landscape analysis of publishers, new initiatives (such as the new work just commissioned by the Wellcome and UKRI on behalf of cOAlition S on providing a framework to enable more transparent communication of OA publishing services and prices; http://www.informationpower.co.uk/news/press-release-transparent-comms-of-oa-services-and-prices/) and the current transparency around APCs and explore the range of direct and indirect costs of what constitutes an APC.

Author Biography

Michael Markie, F1000

Michael Markie is the Publishing Director for F1000 Platforms. He is an open science, open data and open research advocate leading F1000’s effort to change the way science is communicated. He played a pivotal role in devising the open research publishing model and launching F1000Research in 2013, and now oversees the  development of the publishing platform services F1000 provide for leading funders and institutions such Wellcome and Bill and Melinda Gates Foundation. Michael is an active member of the open science community and gives many talks/seminars/workshops on the subject at international conferences and research institutions. Michael previously studied Chemical Biology at the University of Leeds, where he worked on synthesising a range of potential anti-tumour compounds.